Leuvectin cancer gene therapy containing a gene for interleukin-2 to be injected directly into tumors: Began Phase I/II trial in 25 patients to evaluate safety

Vical Inc. (VICL), San Diego Product: Leuvectin cancer gene therapy containing a gene for interleukin-2 to be injected directly into tumors, causing cancer cells to produce IL-2 in order to stimulate ...